Leslie Shaw to alpha-Synuclein
This is a "connection" page, showing publications Leslie Shaw has written about alpha-Synuclein.
Connection Strength
1.106
-
Tosun D, Hausle Z, Thropp P, Concha-Marambio L, Lamoureux J, Lebovitz R, Shaw LM, Singleton AB, Weiner MW, Blauwendraat C. Association of CSF a-synuclein seed amplification assay positivity with disease progression and cognitive decline: A longitudinal Alzheimer's Disease Neuroimaging Initiative study. Alzheimers Dement. 2024 Dec; 20(12):8444-8460.
Score: 0.230
-
Tosun D, Hausle Z, Iwaki H, Thropp P, Lamoureux J, Lee EB, MacLeod K, McEvoy S, Nalls M, Perrin RJ, Saykin AJ, Shaw LM, Singleton AB, Lebovitz R, Weiner MW, Blauwendraat C. A cross-sectional study of a-synuclein seed amplification assay in Alzheimer's disease neuroimaging initiative: Prevalence and associations with Alzheimer's disease biomarkers and cognitive function. Alzheimers Dement. 2024 08; 20(8):5114-5131.
Score: 0.223
-
Mollenhauer B, Caspell-Garcia CJ, Coffey CS, Taylor P, Singleton A, Shaw LM, Trojanowski JQ, Frasier M, Simuni T, Iranzo A, Oertel W, Siderowf A, Weintraub D, Seibyl J, Toga AW, Tanner CM, Kieburtz K, Chahine LM, Marek K, Galasko D. Longitudinal analyses of cerebrospinal fluid a-Synuclein in prodromal and early Parkinson's disease. Mov Disord. 2019 09; 34(9):1354-1364.
Score: 0.160
-
Mollenhauer B, Bowman FD, Drake D, Duong J, Blennow K, El-Agnaf O, Shaw LM, Masucci J, Taylor P, Umek RM, Dunty JM, Smith CL, Stoops E, Vanderstichele H, Schmid AW, Moniatte M, Zhang J, Kruse N, Lashuel HA, Teunissen C, Schubert T, Dave KD, Hutten SJ, Zetterberg H. Antibody-based methods for the measurement of a-synuclein concentration in human cerebrospinal fluid - method comparison and round robin study. J Neurochem. 2019 04; 149(1):126-138.
Score: 0.152
-
Akhtar RS, Licata JP, Luk KC, Shaw LM, Trojanowski JQ, Lee VM. Measurements of auto-antibodies to a-synuclein in the serum and cerebral spinal fluids of patients with Parkinson's disease. J Neurochem. 2018 06; 145(6):489-503.
Score: 0.148
-
Duong MT, Das SR, Khandelwal P, Lyu X, Xie L, McGrew E, Dehghani N, McMillan CT, Lee EB, Shaw LM, Yushkevich PA, Wolk DA, Nasrallah IM. Hypometabolic mismatch with atrophy and tau pathology in mixed Alzheimer's and Lewy body disease. Brain. 2025 May 13; 148(5):1577-1587.
Score: 0.060
-
Cousins KAQ, Irwin DJ, Chen-Plotkin A, Shaw LM, Arezoumandan S, Lee EB, Wolk DA, Weintraub D, Spindler M, Deik A, Grossman M, Tropea TF. Plasma GFAP associates with secondary Alzheimer's pathology in Lewy body disease. Ann Clin Transl Neurol. 2023 05; 10(5):802-813.
Score: 0.052
-
Cousins KAQ, Arezoumandan S, Shellikeri S, Ohm D, Shaw LM, Grossman M, Wolk D, McMillan CT, Chen-Plotkin A, Lee E, Trojanowski JQ, Zetterberg H, Blennow K, Irwin DJ. CSF Biomarkers of Alzheimer Disease in Patients With Concomitant a-Synuclein Pathology. Neurology. 2022 Nov 14; 99(20):e2303-e2312.
Score: 0.050
-
Podlesniy P, Vilas D, Taylor P, Shaw LM, Tolosa E, Trullas R. Mitochondrial DNA in CSF distinguishes LRRK2 from idiopathic Parkinson's disease. Neurobiol Dis. 2016 Oct; 94:10-7.
Score: 0.032